|
|
|
Insider
Information: |
Siegel Jolie |
Relationship: |
Chief Legal Officer |
City: |
Cambridge |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
2 |
|
Direct
Shares |
53,840 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$0 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
53,840 |
|
|
Total
Value |
$0 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Neon Therapeutics, Inc. |
NTGN |
VP, General Counsel |
2020-05-06 |
0 |
2019-02-27 |
0 |
Premium* |
|
C4 Therapeutics, Inc. |
CCCC |
Chief Legal Officer |
2024-09-16 |
53,840 |
2021-07-29 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
20 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
CCCC |
C4 Therapeutics, Inc. |
Chief Legal Officer |
|
2021-07-29 |
4 |
OE |
$4.98 |
$62,250 |
D/D |
12,500 |
12,500 |
0 |
- |
|
CCCC |
C4 Therapeutics, Inc. |
Chief Legal Officer |
|
2021-07-29 |
4 |
AS |
$45.00 |
$562,500 |
D/D |
(12,500) |
0 |
0 |
- |
|
CCCC |
C4 Therapeutics, Inc. |
Chief Legal Officer |
|
2021-09-10 |
4 |
AS |
$50.00 |
$625,000 |
D/D |
(12,500) |
0 |
0 |
- |
|
CCCC |
C4 Therapeutics, Inc. |
Chief Legal Officer |
|
2021-09-10 |
4 |
OE |
$4.98 |
$62,250 |
D/D |
12,500 |
12,500 |
0 |
- |
|
CCCC |
C4 Therapeutics, Inc. |
Chief Legal Officer |
|
2022-05-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,750 |
3,750 |
0 |
- |
|
CCCC |
C4 Therapeutics, Inc. |
Chief Legal Officer |
|
2023-01-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,750 |
6,398 |
0 |
- |
|
CCCC |
C4 Therapeutics, Inc. |
Chief Legal Officer |
|
2023-01-30 |
4 |
D |
$7.78 |
$10,122 |
D/D |
(1,301) |
5,097 |
0 |
- |
|
CCCC |
C4 Therapeutics, Inc. |
Chief Legal Officer |
|
2023-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
25,097 |
0 |
- |
|
CCCC |
C4 Therapeutics, Inc. |
Chief Legal Officer |
|
2023-08-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,250 |
27,347 |
0 |
- |
|
CCCC |
C4 Therapeutics, Inc. |
Chief Legal Officer |
|
2023-08-30 |
4 |
D |
$2.93 |
$1,937 |
D/D |
(661) |
26,686 |
0 |
- |
|
CCCC |
C4 Therapeutics, Inc. |
Chief Legal Officer |
|
2024-02-13 |
4 |
D |
$6.53 |
$11,330 |
D/D |
(1,735) |
24,951 |
0 |
- |
|
CCCC |
C4 Therapeutics, Inc. |
Chief Legal Officer |
|
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
27,300 |
52,251 |
0 |
- |
|
CCCC |
C4 Therapeutics, Inc. |
Chief Legal Officer |
|
2024-09-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,250 |
54,501 |
0 |
- |
|
CCCC |
C4 Therapeutics, Inc. |
Chief Legal Officer |
|
2024-09-16 |
4 |
D |
$6.36 |
$4,204 |
D/D |
(661) |
53,840 |
0 |
- |
|
NTGN |
Neon Therapeutics, Inc. |
VP, General Counsel |
|
2019-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
0 |
- |
|
NTGN |
Neon Therapeutics, Inc. |
VP, General Counsel |
|
2019-11-25 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
105,000 |
0 |
- |
|
NTGN |
Neon Therapeutics, Inc. |
VP, General Counsel |
|
2020-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
65,000 |
170,000 |
0 |
- |
|
NTGN |
Neon Therapeutics, Inc. |
VP, General Counsel |
|
2020-02-25 |
4 |
D |
$1.51 |
$8,054 |
D/D |
(5,334) |
164,666 |
0 |
- |
|
NTGN |
Neon Therapeutics, Inc. |
VP, General Counsel |
|
2020-02-29 |
4 |
D |
$1.50 |
$4,268 |
D/D |
(2,845) |
161,821 |
0 |
- |
|
NTGN |
Neon Therapeutics, Inc. |
VP, General Counsel |
|
2020-05-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(161,821) |
0 |
0 |
- |
|
20 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|